Relapsed Refractory Classical Hodgkin Lymphoma clinical trials

Explore recruiting relapsed refractory classical hodgkin lymphoma clinical trials.

Recruiting relapsed refractory classical hodgkin lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Refractory Classical Hodgkin Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Italy, Denmark, Spain, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)

Germany, Czechia, Belgium, Sweden, France, Spain +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/II Study of Pembrolizumab (MK-3475) in children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)

Italy, Germany, Sweden, France, Netherlands, Portugal

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Relapsed Refractory Classical Hodgkin Lymphoma trials by city

Relapsed Refractory Classical Hodgkin Lymphoma in Toronto Relapsed Refractory Classical Hodgkin Lymphoma in Vancouver Relapsed Refractory Classical Hodgkin Lymphoma in Montreal Relapsed Refractory Classical Hodgkin Lymphoma in Calgary Relapsed Refractory Classical Hodgkin Lymphoma in Edmonton Relapsed Refractory Classical Hodgkin Lymphoma in Ottawa Relapsed Refractory Classical Hodgkin Lymphoma in Winnipeg Relapsed Refractory Classical Hodgkin Lymphoma in Quebec City Relapsed Refractory Classical Hodgkin Lymphoma in Hamilton Relapsed Refractory Classical Hodgkin Lymphoma in Kitchener Relapsed Refractory Classical Hodgkin Lymphoma in London Relapsed Refractory Classical Hodgkin Lymphoma in Halifax Relapsed Refractory Classical Hodgkin Lymphoma in New York Relapsed Refractory Classical Hodgkin Lymphoma in Los Angeles Relapsed Refractory Classical Hodgkin Lymphoma in Chicago Relapsed Refractory Classical Hodgkin Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease